Longitudinal changes in placental biomarkers in women with early versus late placental dysfunction

References

• Brosens I, Pijnenborg R, Vercruysse L, et al. The“Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011;204(3):193–201.
   PubMed Web of Science ®Google Scholar
• Khong Y, Brosens I. Defective deep placentation. Best Pract Res Clin Obstet Gynaecol. 2011;25(3):301–311.
   PubMed Web of Science ®Google Scholar
• Romero R, Kusanovic JP, Chaiworapongsa T, et al. Placental bed disorders in preterm labor, preterm PROM, spontaneous abortion and abruptio placentae. Best Pract Res Clin Obstet Gynaecol. 2011;25(3):313–327.
   PubMed Web of Science ®Google Scholar
• Brosens I. Placental bed & maternal - fetal disorders Preface. Best Pract Res Clin Obstet Gynaecol. 2011;25(3):247–248.
   PubMed Web of Science ®Google Scholar
• Frusca T, Morassi L, Pecorelli S, et al. Histological features of uteroplacental vessels in normal and hypertensive patients in relation to birthweight. Br J Obstet Gynaecol. 1989;96(7):835–839.
   PubMedGoogle Scholar
• Hustin J, Foidart JM, Lambotte R. Maternal vascular lesions in pre-eclampsia and intrauterine growth retardation: light microscopy and immunofluorescence. Placenta. 1983;4:489–498.
   PubMed Web of Science ®Google Scholar
• Cantwell R, Clutton-Brock T, Cooper G, et al. Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG. 2011;118(Suppl 1):1–203.
   PubMed Web of Science ®Google Scholar
• Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323–33.
   PubMed Web of Science ®Google Scholar
• Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116(2 Pt 1):402–414.
   PubMed Web of Science ®Google Scholar
• Villa PM, Marttinen P, Gillberg J, et al. Cluster analysis to estimate the risk of preeclampsia in the high-risk Prediction and Prevention of Preeclampsia and Intrauterine Growth Restriction (PREDO) study. PLoS One. 2017;12(3):e0174399.
   PubMed Web of Science ®Google Scholar
• Frampton GK, Jones J, Rose M, et al. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis. Health Technol Assess. 2016;20(87):1–160.
   Web of Science ®Google Scholar
• Groom KM, David AL. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. Am J Obstet Gynecol. 2018;218(2S):S829–S40.
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer. 2011;2(12):1097–1105.
   PubMedGoogle Scholar
• Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. J Hum Hypertens. 2017;31(12):782–786.
   PubMed Web of Science ®Google Scholar
• Vrachnis N, Kalampokas E, Sifakis S, et al. Placental growth factor (PlGF): A key to optimizing fetal growth. J Matern Fetal Neonatal Med. 2013;26(10):995–1002.
   PubMed Web of Science ®Google Scholar
• Weissgerber T, Rajakumar A, Myerski AC, et al. Vascular pool of releasable soluble VEGF receptor-1 (sFLT1) in women with previous preeclampsia and uncomplicated pregnancy. J Clin Endocrinol Metab. 2014 Mar;99(3):978–987. . Epub 2013 Dec 11.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min J-Y, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003 Mar;111(5):649–658.
   PubMed Web of Science ®Google Scholar
• Herzog EM, Eggink AH, Reijnierse A, et al. Impact of early- and late-onset preeclampsia on features of placental and newborn vascular health. Placenta. 2017;49:72-79.
   Google Scholar
• Redman CW, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol. 2015;213(4Suppl):S9e1, S9–11.
   PubMedGoogle Scholar
• Pinheiro CC, Rayol P, Gozzani L, et al. The relationship of angiogenic factors to maternal and neonatal manifestations of early-onset and late-onset preeclampsia. Prenat Diagn. 2014;34(11):1084–1092.
   PubMed Web of Science ®Google Scholar
• Zhang X, Jia H, Wang Y, et al. Early and late onset severe preeclampsia: a clinicopathologic study of 178 placentas. Zhonghua Bing Li Xue Za Zhi. 2015;44(12):879–883.
   PubMedGoogle Scholar
• Redman WC. Early and late onset preeclampsia: two sides of the same coin. Pregnancy Hypertens. 2017 Jan;7.
   Google Scholar
• Thilaganathan B. Association of Higher Maternal Blood Pressure With Lower Infant Birthweight: placental Cause or Cardiovascular Effect?. Hypertension. 2016;67(3):499–500.
   PubMed Web of Science ®Google Scholar
• Kalafat E, Thilaganathan B. Cardiovascular origins of preeclampsia. Curr Opin Obstet Gynecol. 2017 Dec;29(6):383–389.
   PubMed Web of Science ®Google Scholar
• Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol. 1996 Nov;175(5):1365–1370.
   PubMed Web of Science ®Google Scholar
• Brandao AH, Felix LR, Patricio Edo C, et al. Difference of endothelial function during pregnancies as a method to predict preeclampsia. Arch Gynecol Obstet. 2014;290:471–477.
   PubMed Web of Science ®Google Scholar
• Erez O, Romero R, Espinoza J, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med. 2008;21(5):279–287.
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21(1):9–23.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol. 2004;190(6):1541–7; discussion 7–50.
   Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992–1005.
   PubMed Web of Science ®Google Scholar
• Jaaskelainen T, Heinonen S, Hamalainen E, et al. Angiogenic profile in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort. Pregnancy Hypertens. 2018;14:252-259.
   PubMed Web of Science ®Google Scholar
• Andrietti S, Carlucci S, Wright A, et al. Repeat measurements of uterine artery pulsatility index, mean arterial pressure and serum placental growth factor at 12, 22 and 32 weeks in prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2017;50(2):221–227.
   PubMed Web of Science ®Google Scholar
• Khalil A, Maiz N, Garcia-Mandujano R, et al. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia. Ultrasound Obstet Gynecol. 2016;47(3):324–331.
   PubMed Web of Science ®Google Scholar
• Rana S, Karumanchi SA, Levine RJ, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007;50(1):137–142.
   PubMed Web of Science ®Google Scholar
• Myatt L, Clifton RG, Roberts JM, et al. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?. BJOG. 2013;120(10):1183–1191.
   PubMed Web of Science ®Google Scholar
• Perni U, Sison C, Sharma V, et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension. 2012;59(3):740–746.
   PubMed Web of Science ®Google Scholar
• Davis EF, Lazdam M, Lewandiwski AJ, et al. Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: a systematic review. Pediatrics. 2012;129:e1552–e1561.
   PubMed Web of Science ®Google Scholar
• Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001;20(1):IX–XIV.
   PubMed Web of Science ®Google Scholar
• Rad S, Beauchamp S, Morales C, et al. Defining fetal growth restriction: abdominal circumference as an alternative criterion. J Matern Fetal Neonatal Med. 2018;31(23:3089-3094.
   Web of Science ®Google Scholar
• Powers RW, Jeyabalan A, Clifton RG, et al. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One. 2010;5(10):e13263.
   PubMed Web of Science ®Google Scholar
• Ghosh SK, Raheja S, Tuli A, et al. Can maternal serum placental growth factor estimation in early second trimester predict the occurrence of early onset preclampsia and/or early onset intrauterine growth restriction? A prospective cohort study. J Obstet Gynaecol Res. 2013 May;39(5):881–890.
   PubMed Web of Science ®Google Scholar
• Tsiakkis A. Maternal serum placental growth factor at 12, 22, 32 and 36 weeks’ gestation in screening for preeclampsia. Ultrasound Obstet Gynecol. 2016 Apr;47(4):472–477.
   PubMed Web of Science ®Google Scholar
• MacDonald TM. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks’ gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study. BMC Pregnancy Childbirth. 2018 Aug 31;18(1):354.
   PubMedGoogle Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–683.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Cerdeira AS, Redman C, et al. Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of Preeclampsia: the SaPPPhirE Study. Hypertension. 2018;71(2):306–316.
   PubMed Web of Science ®Google Scholar
• Dover N, Gulerman HC, Celen S, et al. Placental growth factor: as an early second trimester predictive marker for preeclampsia in normal and high-risk pregnancies in a Turkish population. J Obstet Gynaecol India. 2013;63(3):158–163.
   PubMedGoogle Scholar
• Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG. 2012;119(7):778–787.
   PubMed Web of Science ®Google Scholar
• Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1: plGFRatio in Women with Suspected Preeclampsia. N Engl J Med. 2016;374(1):13–22.
   PubMed Web of Science ®Google Scholar
• Navaratnam K, Abreu P, Clarke H, et al. Evaluation of agreement of placental growth factor (PlGF) tests and the soluble FMS-like tyrosine kinase 1 (sFlt-1)/PlGF ratio, comparison of predictive accuracy for pre-eclampsia, and relation to uterine artery Doppler and response to aspirin. J Matern Fetal Neonatal Med. 2019;23(2):179-187.
   Web of Science ®Google Scholar
• Xu B, Shanmugalingam R, Chau K, et al. The effect of acetyl salicylic acid (Aspirin) on trophoblast-endothelial interaction in vitro. J Reprod Immunol. 2017;124:54–61.
   PubMed Web of Science ®Google Scholar
• Panagodage S, Yong HE, Da Silva Costa F, et al. Low-Dose Acetylsalicylic Acid Treatment Modulates the Production of Cytokines and Improves Trophoblast Function in an in Vitro Model of Early-Onset Preeclampsia. Am J Pathol. 2016;186(12):3217–3224.
   PubMed Web of Science ®Google Scholar
• Khalil A, Muttukrishna S, Harrington K, et al. Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS One. 2008;3(7):e2766.
   PubMed Web of Science ®Google Scholar
• Xu B, Thornton C, Tooher J, et al. Effects of anti-hypertensive drugs on production of soluble fms-like tyrosine kinase 1 and soluble endoglin from human normal and pre-eclamptic placentas in vitro. Clin Exp Pharmacol Physiol. 2009;36(8):839–842.
   PubMed Web of Science ®Google Scholar
• Stepan H, Faber R, Dornhofer N, et al. New insights into the biology of preeclampsia. Biol Reprod. 2006 May;74(5):772–776. Epub 2006 Jan.
   PubMed Web of Science ®Google Scholar